FDA Tightens Restrictions on Compounded GLP-1s, Warning Telehealth Firms Including $HIMS
The FDA is tightening restrictions on compounded GLP-1 drugs, warning telehealth firms and saying retatrutide and cagrilintide cannot legally be compounded.
The FDA is tightening restrictions on compounded GLP-1 drugs, warning telehealth firms and saying retatrutide and cagrilintide cannot legally be compounded.